This clinical trial is focused on patients with gynecological cancers who are undergoing a major surgical procedure called pelvic exenteration. This surgery is often performed when the cancer has returned or is persistent. The study is investigating the use of a special dye called Indocyanine Green, which is given as an injection. This dye helps doctors see how well blood is flowing to certain areas during surgery. The main goal is to assess the blood supply to a part of the body called the ileal conduit, which is used to help with urine drainage after surgery. The study also aims to help surgeons decide how much of the ureter, a tube that carries urine from the kidney to the bladder, needs to be removed during the operation.

Participants in the study will receive the Indocyanine Green injection during their surgery. The study will monitor the rate of complications that can occur after surgery, such as blockages where the ureter connects to the ileal conduit, and any leaks from the ureter. Researchers will also look at kidney function over time and track the overall survival and progression-free survival of participants for up to 12 months. The study will help determine if using this dye can improve surgical outcomes and patient recovery.

The trial is expected to run until 2026, and it began recruiting participants in March 2023. This research is important for improving surgical techniques and outcomes for patients with recurrent or persistent gynecological cancers undergoing complex surgeries. By using Indocyanine Green, doctors hope to make more informed decisions during surgery, potentially leading to better recovery and fewer complications for patients.